Engineering Roche’s Next Big Thing: Bispecific Antibodies And Beyond
Executive Summary
Roche’s proficiency at antibody engineering allows it to construct the next-generation molecules needed to translate scientific insights into therapeutic candidates.
You may also be interested in...
Pharmas Pursue Tech Deals To Speed Drug Development, Measure Outcomes
Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.
Roche's Guide To Success In Oncology
Roche's potential in the growing field of immuno-oncology has been a game of wait and see. But now that Tecentriq has launched, the company believes the components are in place to maintain its leadership position in oncology.
For Roche Immuno-Oncology, It’s Steady As She Goes
Roche’s oncology R&D juggernaut gains momentum with surge of combination trials around cancer immunotherapy, illustrated in an animated chart. But the company is keeping its focus on systematically building a base of randomized clinical data to back up efficacy signals for PD-L1 inhibitor Tecentriq